Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 69

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 69
---
 unless the value
of Clearwater Common Stock declines significantly from its value as of the last business day prior to the execution of the Merger Agreement on January 10, 2025. However, it is possible that the value of Clearwater Common Stock (determined as of
such date) will not be sufficient for the “continuity of interest” requirement to be satisfied, in which case the Corporate Mergers would not qualify as a “reorganization,” in which case the Second Merger is not intended to be
completed, and the receipt of the Merger Consideration would be treated as a taxable transaction. Accordingly, Enfusion Stockholders that are U.S. Holders should be aware of the possibility that the Merger may not qualify as a
“reorganization” under Section 368(a) of the Code and that the Merger will be treated as a taxable transaction.

For a more
detailed description of the U.S. federal income tax consequences of the Corporate Mergers, see “The Transactions—Material U.S. Federal Income Tax Consequences of the Corporate Mergers.”

Other Risks of Clearwater and Enfusion

Clearwater’s and Enfusion’s businesses are and will be subject to the risks described above. In addition, Clearwater and Enfusion
are, and will continue to be, subject to the risks described in Clearwater’s Annual

41

Report for the fiscal year ended December 31, 2023 and Enfusion’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as
updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, all of which are filed with the SEC and incorporated by reference into this Proxy
Statement/Prospectus. The risks described above and in those filings represent all known material risks with respect to Clearwater’s and Enfusion’s businesses. See the section titled “Where You Can Find More Information” for the
location of information incorporated by reference into this Proxy Statement/Prospectus.

42

INFORMATION ABOUT ENFUSION

Enfusion, Inc. and Enfusion Ltd. LLC

Enfusion, Inc., a Delaware corporation, is a global, high-growth, software-as-a-service provider focused on transforming the investment management industry. The products and services that comprise its solution are designed to eliminate technology and information
barriers, empowering investment managers to confidently make and execute better-informed investment decisions in real time. Enfusion’s platform simpl